Close

Anti-LMP2 T cell receptor ((NB20)-2), pCDTCR1 (TCR-YC0632)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

It has proved that a subset of alloreactive interactions that include allo-MHC–restricted TCR/MHC recognition events is very analogous to self-restricted TCR/MHC interactions and involves high specificity for MHC-bound peptide. NB20 bound its alloligand HLA-A2-CLG with a Kd in the range of self-restricted interactions and did not bind irrelevant HLA-A2 peptides or other class I MHC molecules, consistent with the properties of the NB20 T-cell clone and analogous to self-restricted TCRs. Use of CLG variants underlined the importance of multiple peptide residues in NB20 recognition, most of which (L5, L6, and M8) have large exposed side chains prominently positioned in the alloligand structure, indicating direct interaction. In contrast, CLG recognition was unaffected by P1 substitution in the least prominent section of CLG.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • LMP2
  • Epitope
  • CLAGLLTMV
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A*02:01
  • Targeting Diseases
  • Tumor
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • NB20
  • Host Species
  • Human

Target

  • Introduction
  • Manipulation of T-cell allorecognition offers the prospect of powerful new therapies for hematological and solid tumors. Importantly, although a minority of tumor-associated antigens (TAAs) are truly tumor-specific, many others, including universal TAAs, are expressed to some extent on untransformed tissues and in the thymus at levels sufficient to mediate effective antigen-specific T-cell tolerance. The result is a mature repertoire of self-MHC–restricted T cells devoid of potent effector capacity targeting specific TAAs. Such effects, thought to apply to several universal TAAs, such as the tumor suppressor p53, the p53 regulator protein MDM2, Cyclin D1, and Wilms' tumor antigen WT1, contribute to poor autologous tumor immunity and represent a major hurdle in cancer immunotherapy.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-LMP2 T cell receptor ((NB20)-2), pCDTCR1 (TCR-YC0632). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.